Annual Revenue
$1.08 M
-$299.40 K-21.76%
December 31, 2023
Summary
- As of February 8, 2025, CYTH annual revenue is $1.08 million, with the most recent change of -$299.40 thousand (-21.76%) on December 31, 2023.
- During the last 3 years, CYTH annual revenue has risen by +$173.00 thousand (+19.15%).
- CYTH annual revenue is now -36.43% below its all-time high of $1.69 million, reached on December 31, 2013.
Performance
CYTH Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Revenue
$233.80 K
+$110.70 K+89.93%
September 30, 2024
Summary
- As of February 8, 2025, CYTH quarterly revenue is $233.80 thousand, with the most recent change of +$110.70 thousand (+89.93%) on September 30, 2024.
- Over the past year, CYTH quarterly revenue has dropped by -$77.60 thousand (-24.92%).
- CYTH quarterly revenue is now -66.99% below its all-time high of $708.30 thousand, reached on June 30, 2013.
Performance
CYTH Quarterly Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Related metrics
TTM Revenue
$870.70 K
-$261.70 K-23.11%
September 30, 2024
Summary
- As of February 8, 2025, CYTH TTM revenue is $870.70 thousand, with the most recent change of -$261.70 thousand (-23.11%) on September 30, 2024.
- Over the past year, CYTH TTM revenue has dropped by -$205.70 thousand (-19.11%).
- CYTH TTM revenue is now -50.92% below its all-time high of $1.77 million, reached on September 30, 2022.
Performance
CYTH TTM Revenue Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
CYTH Revenue Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -21.8% | -24.9% | -19.1% |
| 3 y3 years | +19.1% | -24.9% | -19.1% |
| 5 y5 years | +6.4% | -24.9% | -19.1% |
CYTH Revenue Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -32.1% | at low | -60.0% | +99.7% | -50.9% | at low |
| 5 y | 5-year | -32.1% | +19.1% | -60.0% | +99.7% | -50.9% | at low |
| alltime | all time | -36.4% | +271.9% | -67.0% | +363.0% | -50.9% | +1186.1% |
Cyclo Therapeutics Revenue History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $233.80 K(+89.9%) | $870.70 K(-23.1%) |
| Jun 2024 | - | $123.10 K(-39.2%) | $1.13 M(+0.5%) |
| Mar 2024 | - | $202.40 K(-35.0%) | $1.13 M(+4.6%) |
| Dec 2023 | $1.08 M(-21.8%) | $311.40 K(-37.2%) | $1.08 M(+13.1%) |
| Sep 2023 | - | $495.50 K(+323.1%) | $951.80 K(+4.8%) |
| Jun 2023 | - | $117.10 K(-23.2%) | $908.50 K(-31.9%) |
| Mar 2023 | - | $152.40 K(-18.4%) | $1.33 M(-3.1%) |
| Dec 2022 | $1.38 M(-13.2%) | $186.80 K(-58.7%) | $1.38 M(-22.5%) |
| Sep 2022 | - | $452.20 K(-16.6%) | $1.77 M(+2.8%) |
| Jun 2022 | - | $541.90 K(+178.0%) | $1.73 M(+21.3%) |
| Mar 2022 | - | $194.90 K(-66.7%) | $1.42 M(-10.3%) |
| Dec 2021 | $1.59 M(+75.5%) | $585.10 K(+44.9%) | $1.59 M(+38.3%) |
| Sep 2021 | - | $403.90 K(+69.3%) | $1.15 M(+18.8%) |
| Jun 2021 | - | $238.60 K(-33.4%) | $964.80 K(+3.1%) |
| Mar 2021 | - | $358.10 K(+145.9%) | $935.80 K(+3.6%) |
| Dec 2020 | $903.40 K(-10.3%) | $145.60 K(-34.6%) | $903.40 K(-8.3%) |
| Sep 2020 | - | $222.50 K(+6.2%) | $985.20 K(-6.0%) |
| Jun 2020 | - | $209.60 K(-35.6%) | $1.05 M(-5.7%) |
| Mar 2020 | - | $325.70 K(+43.2%) | $1.11 M(+10.4%) |
| Dec 2019 | $1.01 M(-0.4%) | $227.40 K(-20.5%) | $1.01 M(-1.2%) |
| Sep 2019 | - | $285.90 K(+4.7%) | $1.02 M(+6.4%) |
| Jun 2019 | - | $273.10 K(+23.7%) | $957.90 K(-7.4%) |
| Mar 2019 | - | $220.80 K(-7.8%) | $1.03 M(+2.2%) |
| Dec 2018 | $1.01 M(-18.3%) | $239.50 K(+6.7%) | $1.01 M(+7.5%) |
| Sep 2018 | - | $224.50 K(-35.7%) | $940.50 K(-1.7%) |
| Jun 2018 | - | $349.40 K(+76.4%) | $957.10 K(-15.4%) |
| Mar 2018 | - | $198.10 K(+17.6%) | $1.13 M(-8.6%) |
| Dec 2017 | $1.24 M(-17.6%) | $168.50 K(-30.1%) | $1.24 M(-22.5%) |
| Sep 2017 | - | $241.10 K(-53.9%) | $1.60 M(-2.3%) |
| Jun 2017 | - | $523.10 K(+71.5%) | $1.63 M(+9.3%) |
| Mar 2017 | - | $305.10 K(-42.2%) | $1.50 M(-0.5%) |
| Dec 2016 | $1.50 M(+58.1%) | $527.60 K(+89.6%) | $1.50 M(+32.1%) |
| Sep 2016 | - | $278.20 K(-27.6%) | $1.14 M(+4.0%) |
| Jun 2016 | - | $384.40 K(+22.9%) | $1.09 M(+0.4%) |
| Mar 2016 | - | $312.70 K(+92.7%) | $1.09 M(+14.7%) |
| Dec 2015 | $950.50 K(-39.4%) | $162.30 K(-30.8%) | $950.50 K(-23.0%) |
| Sep 2015 | - | $234.70 K(-38.3%) | $1.23 M(-11.0%) |
| Jun 2015 | - | $380.30 K(+119.6%) | $1.39 M(+17.5%) |
| Mar 2015 | - | $173.20 K(-61.2%) | $1.18 M(-24.7%) |
| Dec 2014 | $1.57 M(-7.4%) | $446.00 K(+15.1%) | $1.57 M(+15.6%) |
| Sep 2014 | - | $387.50 K(+123.2%) | $1.36 M(+19.4%) |
| Jun 2014 | - | $173.60 K(-69.0%) | $1.14 M(-32.0%) |
| Mar 2014 | - | $560.30 K(+139.2%) | $1.67 M(-1.4%) |
| Dec 2013 | $1.69 M(+62.1%) | $234.20 K(+40.0%) | $1.69 M(-3.6%) |
| Sep 2013 | - | $167.30 K(-76.4%) | $1.76 M(+0.6%) |
| Jun 2013 | - | $708.30 K(+21.4%) | $1.75 M(+47.2%) |
| Mar 2013 | - | $583.50 K(+96.1%) | $1.19 M(+13.6%) |
| Dec 2012 | $1.04 M | $297.50 K(+89.0%) | $1.04 M(+13.0%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2012 | - | $157.40 K(+6.2%) | $924.40 K(-7.4%) |
| Jun 2012 | - | $148.20 K(-66.5%) | $998.20 K(-18.1%) |
| Mar 2012 | - | $441.90 K(+149.8%) | $1.22 M(+18.2%) |
| Dec 2011 | $1.03 M(+28.6%) | $176.90 K(-23.5%) | $1.03 M(-8.6%) |
| Sep 2011 | - | $231.20 K(-37.4%) | $1.13 M(+3.2%) |
| Jun 2011 | - | $369.30 K(+45.2%) | $1.09 M(+24.4%) |
| Mar 2011 | - | $254.40 K(-7.3%) | $879.90 K(+10.7%) |
| Dec 2010 | $802.40 K(+28.6%) | $274.40 K(+39.6%) | $795.00 K(+16.2%) |
| Sep 2010 | - | $196.50 K(+27.1%) | $684.20 K(-2.7%) |
| Jun 2010 | - | $154.60 K(-8.8%) | $703.00 K(+4.5%) |
| Mar 2010 | - | $169.50 K(+3.6%) | $672.80 K(+7.9%) |
| Dec 2009 | $623.90 K(+26.1%) | $163.60 K(-24.0%) | $623.80 K(+6.8%) |
| Sep 2009 | - | $215.30 K(+73.1%) | $583.90 K(+14.3%) |
| Jun 2009 | - | $124.40 K(+3.2%) | $510.70 K(-6.6%) |
| Mar 2009 | - | $120.50 K(-2.6%) | $547.00 K(+10.5%) |
| Dec 2008 | $494.90 K(-34.1%) | $123.70 K(-12.9%) | $495.00 K(-12.4%) |
| Sep 2008 | - | $142.10 K(-11.6%) | $564.80 K(-13.0%) |
| Jun 2008 | - | $160.70 K(+134.6%) | $649.40 K(-2.8%) |
| Mar 2008 | - | $68.50 K(-64.6%) | $668.40 K(-11.0%) |
| Dec 2007 | $751.20 K(+38.5%) | $193.50 K(-14.6%) | $751.20 K(+8.4%) |
| Sep 2007 | - | $226.70 K(+26.2%) | $692.80 K(+19.6%) |
| Jun 2007 | - | $179.70 K(+18.8%) | $579.10 K(+9.9%) |
| Mar 2007 | - | $151.30 K(+12.0%) | $526.80 K(-2.9%) |
| Dec 2006 | $542.30 K(+19.3%) | $135.10 K(+19.6%) | $542.30 K(+11.0%) |
| Sep 2006 | - | $113.00 K(-11.3%) | $488.40 K(-1.2%) |
| Jun 2006 | - | $127.40 K(-23.6%) | $494.30 K(-1.7%) |
| Mar 2006 | - | $166.80 K(+105.4%) | $502.60 K(+10.6%) |
| Dec 2005 | $454.40 K(-2.2%) | $81.20 K(-31.7%) | $454.30 K(+0.9%) |
| Sep 2005 | - | $118.90 K(-12.4%) | $450.20 K(-3.3%) |
| Jun 2005 | - | $135.70 K(+14.5%) | $465.40 K(+3.4%) |
| Mar 2005 | - | $118.50 K(+53.7%) | $449.90 K(-3.2%) |
| Dec 2004 | $464.70 K(+17.8%) | $77.10 K(-42.5%) | $464.60 K(-16.5%) |
| Sep 2004 | - | $134.10 K(+11.6%) | $556.50 K(+9.6%) |
| Jun 2004 | - | $120.20 K(-9.8%) | $507.90 K(+6.4%) |
| Mar 2004 | - | $133.20 K(-21.2%) | $477.20 K(+21.0%) |
| Dec 2003 | $394.50 K(-24.5%) | $169.00 K(+97.7%) | $394.50 K(+38.8%) |
| Sep 2003 | - | $85.50 K(-4.5%) | $284.30 K(-15.3%) |
| Jun 2003 | - | $89.50 K(+77.2%) | $335.50 K(-11.0%) |
| Mar 2003 | - | $50.50 K(-14.1%) | $377.00 K(-27.8%) |
| Dec 2002 | $522.40 K(+80.5%) | $58.80 K(-57.0%) | $522.30 K(+0.7%) |
| Sep 2002 | - | $136.70 K(+4.4%) | $518.90 K(+17.0%) |
| Jun 2002 | - | $131.00 K(-33.1%) | $443.50 K(+11.6%) |
| Mar 2002 | - | $195.80 K(+253.4%) | $397.30 K(+37.2%) |
| Dec 2001 | $289.40 K(-16.6%) | $55.40 K(-9.6%) | $289.50 K(-0.9%) |
| Sep 2001 | - | $61.30 K(-27.7%) | $292.20 K(-2.1%) |
| Jun 2001 | - | $84.80 K(-3.6%) | $298.60 K(+39.7%) |
| Mar 2001 | - | $88.00 K(+51.5%) | $213.80 K(+70.0%) |
| Dec 2000 | $347.20 K | $58.10 K(-14.2%) | $125.80 K(+85.8%) |
| Sep 2000 | - | $67.70 K | $67.70 K |
FAQ
- What is Cyclo Therapeutics annual revenue?
- What is the all time high annual revenue for Cyclo Therapeutics?
- What is Cyclo Therapeutics annual revenue year-on-year change?
- What is Cyclo Therapeutics quarterly revenue?
- What is the all time high quarterly revenue for Cyclo Therapeutics?
- What is Cyclo Therapeutics quarterly revenue year-on-year change?
- What is Cyclo Therapeutics TTM revenue?
- What is the all time high TTM revenue for Cyclo Therapeutics?
- What is Cyclo Therapeutics TTM revenue year-on-year change?
What is Cyclo Therapeutics annual revenue?
The current annual revenue of CYTH is $1.08 M
What is the all time high annual revenue for Cyclo Therapeutics?
Cyclo Therapeutics all-time high annual revenue is $1.69 M
What is Cyclo Therapeutics annual revenue year-on-year change?
Over the past year, CYTH annual revenue has changed by -$299.40 K (-21.76%)
What is Cyclo Therapeutics quarterly revenue?
The current quarterly revenue of CYTH is $233.80 K
What is the all time high quarterly revenue for Cyclo Therapeutics?
Cyclo Therapeutics all-time high quarterly revenue is $708.30 K
What is Cyclo Therapeutics quarterly revenue year-on-year change?
Over the past year, CYTH quarterly revenue has changed by -$77.60 K (-24.92%)
What is Cyclo Therapeutics TTM revenue?
The current TTM revenue of CYTH is $870.70 K
What is the all time high TTM revenue for Cyclo Therapeutics?
Cyclo Therapeutics all-time high TTM revenue is $1.77 M
What is Cyclo Therapeutics TTM revenue year-on-year change?
Over the past year, CYTH TTM revenue has changed by -$205.70 K (-19.11%)